Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE1C | Q14123 | 14/20 | 0.44 |
| ▸ | PDE1B | Q01064 | 11/20 | 0.43 |
| ▸ | PDE1A | P54750 | 10/20 | 0.43 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL400651 | 0.95 | PDE1C (0.43) | PDE1CPDE1BPDE1ATNK2KCNH2 | |
| SCHEMBL18099738 | 0.93 | PDE1C (0.46) | PDE1CPDE1BPDE1ATNK2FGFR1 | |
| SCHEMBL4313118 | 0.92 | PDE1C (0.40) | PDE1CPDE1BPDE1ATNK2 | |
| SCHEMBL13962521 | 0.92 | PDE1C (0.47) | PDE1CPDE1BPDE1ATNK2 | |
| SCHEMBL2327173 | 0.89 | PDE1C (0.50) | PDE1CPDE1BPDE1A | |
| SCHEMBL13962531 | 0.89 | PDE1C (0.37) | PDE1CPDE1BPDE1ATNK2 | |
| SCHEMBL397982 | 0.89 | PDE1C (0.43) | PDE1CPDE1BPDE1ATNK2 | |
| SCHEMBL397983 | 0.89 | PDE1C (0.43) | PDE1CPDE1BPDE1ATNK2 | |
| SCHEMBL23217412 | 0.88 | PDE1C (0.42) | PDE1CPDE1BPDE1A | |
| SCHEMBL2321250 | 0.88 | PDE1C (0.36) | PDE1CPDE1BPDE1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025067411-A1 | NEK7 INHIBITOR, PHARMACEUTICAL COMPOSITION AND USE THEREOF | 北京普祺医药科技股份有限公司 | 2025-04-03 | — | — | WO | disclosed |
| US-12162890-B2 | Heteroaromatic NMDA receptor modulators and uses thereof | NOVARTIS AG (CH) | 2024-12-10 | — | — | US | disclosed |
| US-20230023543-A1 | HETEROAROMATIC NMDA RECEPTOR MODULATORS AND USES THEREOF | NOVARTIS AG (CH) | 2023-01-26 | — | — | US | disclosed |
| US-20230023543-A1 | HETEROAROMATIC NMDA RECEPTOR MODULATORS AND USES THEREOF | NOVARTIS AG (CH) | 2023-01-26 | — | — | US | disclosed |
| US-11472810-B2 | Imidazopyrazinones as PDE1 inhibitors | H. LUNDBECK A/S (DK) | 2022-10-18 | — | — | US | disclosed |
| US-11236104-B2 | Heteroaromatic NMDA receptor modulators and uses thereof | CADENT THERAPEUTICS, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| US-11236104-B2 | Heteroaromatic NMDA receptor modulators and uses thereof | CADENT THERAPEUTICS, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| US-20210238182-A1 | IMIDAZOPYRAZINONES AS PDE1 INHIBITORS | H. LUNDBECK A/S (DK) | 2021-08-05 | — | — | US | disclosed |
| US-20210238182-A1 | IMIDAZOPYRAZINONES AS PDE1 INHIBITORS | H. LUNDBECK A/S (DK) | 2021-08-05 | — | — | US | disclosed |
| US-20210107916-A1 | HETEROAROMATIC NMDA RECEPTOR MODULATORS AND USES THEREOF | NOVARTIS AG (CH) | 2021-04-15 | — | — | US | disclosed |
| WO-2017100591-A1 | HETEROAROMATIC NMDA RECEPTOR MODULATORS AND USES THEREOF | LUC THERAPEUTICS (US) | 2017-06-15 | — | — | WO | disclosed |
| WO-2017100591-A1 | HETEROAROMATIC NMDA RECEPTOR MODULATORS AND USES THEREOF | LUC THERAPEUTICS (US) | 2017-06-15 | — | — | WO | disclosed |
| US-20160318939-A1 | Imidazopyrazinones as PDE1 Inhibitors | H. LUNDBECK A/S (DK) | 2016-11-03 | — | — | US | disclosed |
| US-20160318939-A1 | Imidazopyrazinones as PDE1 Inhibitors | H. LUNDBECK A/S (DK) | 2016-11-03 | — | — | US | disclosed |
| US-20160318939-A1 | Imidazopyrazinones as PDE1 Inhibitors | H. LUNDBECK A/S (DK) | 2016-11-03 | — | — | US | disclosed |
| WO-2016174188-A1 | IMIDAZOPYRAZINONES AS PDE1 INHIBITORS | H. LUNDBECK A/S (DK) | 2016-11-03 | — | — | WO | disclosed |
| WO-2016174188-A1 | IMIDAZOPYRAZINONES AS PDE1 INHIBITORS | H. LUNDBECK A/S (DK) | 2016-11-03 | — | — | WO | disclosed |
| US-20160280711-A1 | Protein Kinase Inhibitors | PHARMASCIENCE INC. (CA) | 2016-09-29 | — | — | US | disclosed |
| US-20160280711-A1 | Protein Kinase Inhibitors | PHARMASCIENCE INC. (CA) | 2016-09-29 | — | — | US | disclosed |
| WO-2015074138-A1 | PROTEIN KINASE INHIBITORS | PHARMASCIENCE INC. (CA) | 2015-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160318939-A1 | Imidazopyrazinones as PDE1 Inhibitors | PDE12, PDE4A, PDE5A | PDE1C 15/4885PDE1B 10/4885PDE1A 7/4885 |
| US-20160280711-A1 | Protein Kinase Inhibitors | TEC, LCK, SRC | PDE1C 1830/4885PDE1B 1977/4885PDE1A 1718/4885 |
| US-11236104-B2 | Heteroaromatic NMDA receptor modulators and uses thereof | GRIN2C, GRIN2A, GRIN1 | PDE1C 1752/4885PDE1B 1688/4885PDE1A 1357/4885 |
| US-12162890-B2 | Heteroaromatic NMDA receptor modulators and uses thereof | GRIN2C, GRIN2A, GRIN1 | PDE1C 1752/4885PDE1B 1688/4885PDE1A 1357/4885 |
| US-20210238182-A1 | IMIDAZOPYRAZINONES AS PDE1 INHIBITORS | PDE12, PDE4A, PDE5A | PDE1C 15/4885PDE1B 10/4885PDE1A 7/4885 |
| US-11472810-B2 | Imidazopyrazinones as PDE1 inhibitors | PDE12, PDE4A, PDE5A | PDE1C 15/4885PDE1B 10/4885PDE1A 7/4885 |
| US-20230023543-A1 | HETEROAROMATIC NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN2C, GRIN2A, GRIN1 | PDE1C 1752/4885PDE1B 1688/4885PDE1A 1357/4885 |
| US-20210107916-A1 | HETEROAROMATIC NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN2C, GRIN2A, GRIN1 | PDE1C 1752/4885PDE1B 1688/4885PDE1A 1357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.